Institution

Kliniken Essen-Mitte

Essen, GermanyWebsite

15running trials
15closed trials
4,035publications (OpenAlex)

Running trials

Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
NCT07230691· Janssen Research & Development, LLC· Source
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
NCT07022483· Phase 3· Daiichi Sankyo· Source
Recruiting
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
NCT06340568· Phase 3· BioNTech SE· Source
Active, not recruiting
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
NCT06430866· Phase 3· Amgen· Source
Recruiting
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
NCT06312176· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus
NCT05714930· Heinrich-Heine University, Duesseldorf· Source
Active, not recruiting
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
NCT04595565· Phase 3· GBG Forschungs GmbH· Source
Active, not recruiting
Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence
NCT03443856· Phase 2· European Organisation for Research and Treatment of Cancer - EORTC· Source
Active, not recruiting
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
NCT03821935· Phase 1· AbbVie· Source
Active, not recruiting
International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer
NCT03386734· Centre Hospitalier Universitaire de Besancon· Source
Recruiting
Endometrial Cancer Lymphadenectomy Trial
NCT03438474· Philipps University Marburg· Source
Active, not recruiting
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
NCT02947685· Phase 3· Alliance Foundation Trials, LLC.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Endometrial cancer3 recruiting
Metastatic breast cancer2 recruiting
Lung cancer1 recruiting
Lupus (SLE)1 recruiting
Ovarian cancer1 recruiting

Closed trials

Completed
A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS)
NCT05546905· Pierre Fabre Medicament· Source
Completed
MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab
NCT04554836· Phase 2· TheraOp· Source
Completed
Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients
NCT04227522· Phase 3· North Eastern German Society of Gynaecological Oncology· Source
Terminated
Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)
NCT03891576· Phase 2· Mario Negri Institute for Pharmacological Research· Source
Completed
Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer
NCT03598270· Phase 3· Grupo Español de Investigación en Cáncer de Ovario· Source
Completed
Atezolizumab Trial in Endometrial Cancer - AtTEnd
NCT03603184· Phase 3· Mario Negri Institute for Pharmacological Research· Source
Completed
Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer
NCT03530267· Phase 2· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source
Completed
Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer
NCT03353831· Phase 3· AGO Research GmbH· Source
Completed
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
NCT03310957· Phase 1/2· Seagen Inc.· Source
Completed
A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
NCT03412773· Phase 3· BeiGene· Source
Completed
Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy
NCT03081143· Phase 2/3· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source
Completed
ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab
NCT02891824· Phase 3· ARCAGY/ GINECO GROUP· Source
Completed
Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma
NCT02205047· Phase 2· European Organisation for Research and Treatment of Cancer - EORTC· Source
Recruiting
Praegnant Breast Cancer: Early/Advanced/Metastatic
NCT02338167· University Hospital Tuebingen· Source
Completed
Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer
NCT01658930· Canadian Cancer Trials Group· Source

Registry name variants (23)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

Kliniken Essen-Mitte
Essen, 45136
12 trials
Kliniken Essen-Mitte - Evang. Huyssens-Stiftung
Essen, Other 45136
6 trials
Kliniken Essen-Mitte; Evangelische Huyssens-Stiftung
Essen, 45136
4 trials
Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung Loc. 1
Essen, 45136
2 trials
- NCT07022483A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
- NCT06340568A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
Kliniken Essen-Mitte, Evang. Huyssens-Stiftung/Knappschaft GmbH
Essen, 45136
2 trials
- NCT04595565Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
- NCT02947685Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
Kliniken Essen Mitte, Essen
Essen, North Rhine-Westphalia 45136
1 trial
- NCT05714930LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus
  Contact: Gamal Chehab, MD
Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung /ID# 269587
Essen, North Rhine-Westphalia 45136
1 trial
- NCT03821935Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung-Klinike für Senologie/ Brustzentrum (Site 1300)
Essen, North Rhine-Westphalia 45136
1 trial
- NCT06312176A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
  Contact: Study Coordinator
Kliniken Essen Mitte, Evang. Huyssens-Stiftung, Internistische Onkologie und Hmatologie mit integire
Essen, 45276
1 trial
- NCT06430866Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
Kliniken Essen Mitte, Evang. Huyssens Stiftung/Knappschaft GmbH, Gynäkologische Onkologie
Essen, 45136
1 trial
- NCT03438474Endometrial Cancer Lymphadenectomy Trial
  Contact: Philipp Harter, MD
Kliniken Essen-Mitte - 2206
Essen, 45136
Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung-Klinike für Senologie/ Brustzentrum (Site 1200
Essen, North Rhine-Westphalia 45136
Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung (Site 0611)
Essen, North Rhine-Westphalia 45136
Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung (Site 1001)
Essen, North Rhine-Westphalia 45136
Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung (Site 1104)
Essen, North Rhine-Westphalia 45136
Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung (Site 1400)
Essen, North Rhine-Westphalia 45136
Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung (Site 2104)
Essen, North Rhine-Westphalia 45136
Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung (Site 2105)
Essen, North Rhine-Westphalia 45136
Kliniken Essen-Mitte - Gynaekologie und Gynaekologische Onkologie
Essen
Kliniken Essen-Mitte/Huyssens-Stift
Essen, 45136
Kliniken Essen Mitte (Site 1012)
Essen, 45136
Kliniken Essen Mitte (Site 1517)
Essen, North Rhine-Westphalia 45136
Kliniken Essen Mitte (Site 1567)
Essen, North Rhine-Westphalia 45136

Conditions

Diseases this institution publishes on or runs trials for.

Ovarian cancer40 works · 8 trials

Institution data: ROR 03v958f45 (CC0-1.0)Updated 10 Nov 2026

Report an error